INOVIQ Ltd engages in the developing and commercializing of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. Its cancer diagnostic pipeline includes internal and partnered diagnostic tests for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.